Patient Rating:

4.9 out of 5

31 Patient Ratings
16 Patient Comments

Sean J. Mulvihill, M.D.

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 581-7167 Huntsman Cancer Institute
Patient Care Center
2000 Circle of Hope
Salt Lake City, UT 84112
Map

Bio

Sean Mulvihill, MD has specialized expertise in the treatment of diseases of the liver, biliary tract, and pancreas. He is board certified in general surgery. His main clinical focus is in the management of patients with pancreatic tumors, such as pancreatic adenocarcinoma and neuroendocrine tumors. He has integrated a research program funded by the National Cancer Institute into his clinical practice, with the aim of determining the underlying cause of these cancers and identifying new treatment approaches. This knowledge is leading to improved diagnostic strategies, improved selection of treatment options, and improved outcomes.

Board Certification and Academic Information

Academic Departments Surgery - Professor
Academic Divisions General Surgery
Board Certification American Board of Surgery (General Surgery)
Cancer Center Programs Experimental Therapeutics

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
5.0
My confidence in care provider
4.9
Time care provider spent with me
4.9
Care provider spoke using clear language
5.0
Care provider's effort to include me in decisions
4.9
Care provider's concern for questions & worries
5.0
Care provider's explanation of condition/problem
4.9
Wait time at clinic
4.5
Care provider's friendliness and courtesy
5.0

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

February 16, 2014

we feel very lucky to have met Dr Mulvihill and have him treating me

February 13, 2014

i would like to say that the doctor, staff , and all are very polite.

February 10, 2014

Encouraging and very clear.

November 27, 2013

all my questions were discussed and I left with a confident feeling that my next steps were to be

October 08, 2013

Dr. Mulvihill is a great doctor and is very pleasant to talk with as well. he was great on answering all our questions and concerns in terms which we understood . My experience with Dr. Mulvihill would be a 100% referral to anyone whom I know would need his assistance as well.

June 25, 2013

excellent and impressed with the knowledge level and with the terminology used for ease of understanding all issues talked about.

May 13, 2013

Extremely positive experience.

January 22, 2013

Came to Dr. Mulvihill by recommendation of a doctor i work for now. Also, he was the specialist that my origional surgeon was talking to. i knew i was in good hands before i arrived. Talking with Dr. Mulvihill in person confirmed that!

October 23, 2012

Always a good experience

June 15, 2012

I feel very confident that I am in good hands

May 12, 2012

All care providers I have met or been counseled by while at Huntsman have been extremely professional and very friendly

March 14, 2012

Dr. Mulvihill was excellent and we enjoyed learning from him and hearing his plan for my treatment. He was very professional, thorough, informative, positive, and kind.

February 18, 2012

Excellent in every respect. Profesional, informative, and personable.

February 11, 2012

My diagnosis was not clear. I hope it will be resolved quickly and given priority. I also wish to be informed of my situation as it progresses.

February 07, 2012

I was very well treated

February 04, 2012

I highly regard Dr. Mulvihill's expertise, mannerism and professionalism. I consider I have access to the best!

Academic Profile

Research Interests

  • Pancreatic cancer
  • Gastrointestinal Physiology
  • Quality of Health Care
  • Clinical Trials in Pancreatic Disease
  • Education, Professional, Retraining

Board Certification and Academic Information

Academic Departments Surgery - Professor
Academic Divisions General Surgery
Board Certification American Board of Surgery (General Surgery)
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 581-4896 Clinical Neurosciences Center
SVP for Health Sciences
175 North Medical Drive East
Salt Lake City, UT 84132

Academic Bio

Dr. Sean Mulvihill is the Chief Executive Officer of the University of Utah Medical Group and Associate Vice President for Clinical Affairs in the University of Utah. He is a tenured professor and holds the Ross R. Anderson Presidential Endowed Chair in Surgery. He is a Huntsman Cancer Institute investigator and member of the Experimental Therapeutics Program. He is part of the leadership team overseeing strategic direction, budgeting, and clinical operations for University of Utah Health Care. He serves, in this role, as a link and connection point for the clinical enterprise with School of Medicine departments.

Prior to assuming his leadership role in University of Utah Health Care, Dr. Mulvihill served as Chair of the Department of Surgery for 12 years and Senior Director for Clinical Affairs in the Huntsman Cancer Institute at the University of Utah for 10 years. He was recruited to the University of Utah from the University of California, San Francisco where he served as Chief of their Division of General Surgery.

Dr. Mulvihill is an editor of a major surgical textbook, Surgery: Basic Science and Clinical Evidence, and has authored over 150 scientific papers, editorials, and book chapters. He is past-president of the American Hepatopancreatobiliary Association and currently serves as an officer or board member of numerous other professional societies.

Dr. Mulvihill’s clinical expertise relates to diseases of the liver, pancreas, and bile ducts. He has worked to improve surgical outcomes and to develop novel treatment strategies for patients with pancreatic cancer and islet cell tumors. As head of the Pancreatic Cancer Research Group at the Huntsman Cancer Institute, he was responsible for the successful development of a clinical research database containing detailed information on patients with pancreatic tumors, linked to a robust biospecimen bank of patient samples. This material is used to develop and validate biomarkers useful in early diagnosis, prediction of response to therapy, and in studies of the cell biology of pancreatic cancer. His research is funded by the National Cancer Institute.

Dr. Mulvihill is particularly interested in navigating the challenges of health care reform by embracing the triple aim of improving individual’s experience of care, improving the health of the population we serve, and reducing the cost of care in University of Utah Health Care.

Education

Education History

Type School Degree
Chief Resident University of California - Los Angeles
General Surgery
Chief Resident
Residency University of California - Los Angeles
General Surgery
Resident
Postdoctoral Fellowship University of California - Los Angeles
GI Research
Postdoctoral Fellow
Residency University of California - Los Angeles
General Surgery
Resident
Internship University of California - Los Angeles
Surgery
Intern
Professional Medical University of Southern California
Medicine
M.D.
Undergraduate University of California - Davis
Zoology
B.S.

Publications

Selected Provider Publications

Journal Article

  1. Poruk KE, Firpo MA, Adler DG, Mulvihill SJ (2013). Screening for pancreatic cancer: why, how, and who? Ann Surg, 257(1), 17-26.
  2. Granger JH, Granger MC, Firpo MA, Mulvihill SJ, Porter MD (2013). Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel. Analyst, 138(2), 410-6.
  3. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, Firpo MA, Mulvihill SJ (2013). The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med, 13(3), 340-51.
  4. Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, Mulvihill SJ (2013). Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas, 42(2), 193-7.
  5. Scaife CL, Hewitt KC, Mone MC, Hansen HJ, Nelson ET, Mulvihill SJ (2013). Comparison of intraoperative versus delayed enteral feeding tube placement in patients undergoing a Whipple procedure.LID - 10.1111/hpb.12072 [doi]. HPB (Oxford).
  6. Scaife CL, Hartz A, Pappas L, Pelletier P, He T, Glasgow RE, Mulvihill SJ (2013). Association Between Postoperative Complications and Clinical Cancer Outcomes. Ann Surg Oncol.
  7. Hazard L, Jones K, Shaban A, Anker C, Scaife C, Weis J, Mulvihill S (2012). Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation. J Gastrointest Cancer, 43(2), 258-66.
  8. Pearson EG, Scaife CL, Mulvihill SJ, Glasgow RE (2012). Roux-en-Y drainage of a pancreatic fistula for disconnected pancreatic duct syndrome after acute necrotizing pancreatitis. HPB (Oxford), 14(1), 26-31.
  9. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA (2012). Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw, 10(6), 703-13.
  10. Jennifer H Granger, Michael C Granger, Matthew A Firpo, Sean J Mulvihill and Marc D Porter (2012). Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel. Analyst, 2013(138), 410-416.
  11. Fukuda A, Wang SC, Morris JP 4th, Folias AE, Liou A, Kim GE, Akira S, Boucher KM, Firpo MA, Mulvihill SJ, Hebrok M (2011). Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell, 19(4), 441-55.
  12. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ (2010). Phenotype and genotype of pancreatic cancer cell lines. Pancreas, 39(4), 425-35.
  13. Shirts BH, Burt RW, Mulvihill SJ, Cannon-Albright LA (2010). A population-based description of familial clustering of pancreatic cancer. Clin Gastroenterol Hepatol, 8(9), 812-6.
  14. Scaife CL, Shea J, Emerson L, Boucher K, Firpo MA, Beckerle MC, Mulvihill SJ (2010). Prognostic significance of PINCH signalling in human pancreatic ductal adenocarcinoma. HPB (Oxford), 12(5), 352-8.
  15. Poruk KE, Firpo MA, Huerter LM, Scaife CL, Emerson LL, Boucher KM, Jones KA, Mulvihill SJ (2010). Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev, 19(10), 2605-10.
  16. Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ (2009). Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg, 33(4), 716-22.
  17. Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, DAngelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX (2009). NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw, 7(4), 350-91.
  18. Pitt HA, Kilbane M, Strasberg SM, Pawlik TM, Dixon E, Zyromski NJ, Aloia TA, Henderson JM, Mulvihill SJ (2009). ACS-NSQIP has the potential to create an HPB-NSQIP option. HPB (Oxford), 11(5), 405-13.
  19. Torgenson MJ, Shea JE, Firpo MA, Dai Q, Mulvihill SJ, Scaife CL (2008). Natural History of Pancreatic Cancer Recurrence Following "Curative" Resection in Athymic Mice. J Surg Res, 149(1), 57-61.
  20. Glasgow RE, Jackson HH, Neumayer L, Schifftner TL, Khuri SF, Henderson WG, Mulvihill SJ (2007). Pancreatic resection in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study. J Am Coll Surg, 204(6), 1252-60.
  21. Lightner AM, Glasgow RE, Jordan TH, Krassner AD, Way LW, Mulvihill SJ, Kirkwood KS (2004). Pancreatic resection in the elderly. J Am Coll Surg, 198(5), 697-706.
  22. Chapman WC, Abecassis M, Jarnagin W, Mulvihill S, Strasberg SM (2003). Bile duct injuries 12 years after the introduction of laparoscopic cholecystectomy. J Gastrointest Surg, 7(3), 412-6.
  23. Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, Verhagen A, Rivera CR, Mulvihill SJ, Malloy MJ, Kane JP (2002). Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest, 110(1), 109-17.

Book

  1. 1 Norton JA, Bollinger RA, Chang AE, Lowry SF, Mulvihill SJ, Pass HI, Thompson RW (2000). Surgery: Basic Science and Clinical Evidence. New York: Springer-Verlag, Inc.

Book Chapter

  1. Scaife CL, Mulvihill SJ (In Press). Open approach to islet cell tumors of the pancreas. In ACS Atlas of Pancreatic Surgery (in press).

Clinical Trials

Video & News